Platelet function and antiplatelet therapy in XXXX : implications of genetic polymorphisms.

@entity1 @entity32 @entity1187 @entity731 @entity1397 @entity117 @entity14315 @entity715 @entity3075 @entity65
Platelets play a crucial role in @entity715 , @entity32 , immunity and @entity731 . Antiplatelet agents are widely used in @entity1 with @entity1187 and other @entity65 . @entity117 and @entity1397 are the most commonly prescribed antiplatelet agents, with a relatively safe profile and efficiency in a variety of clinical conditions. Numerous prospective studies have revealed variability of antiplatelet efficacy. The so called "antiplatelet resistance" prompted a search for mechanisms implicated in poor responsiveness to @entity117 and @entity1397 therapy. In this regard, genetic polymorphisms in the platelet receptor genes attracted considerable interest. Specific genetic variants in platelet receptors such as the @entity3075 , glycoprotein (GP) IIb/IIIa, @entity14315 /IIa, GPIb/IX/V and the cytochrome P450 (CYP) family of genes are associated with variable response to antiplatelet therapy and cardiovascular events. Genetic polymorphisms and haplotypes that comprehensively capture the genetic information encoded within the platelet receptor genes can, to some extent, predict response to the antiplatelet drug better than any single genotype. Genotyping for multiple receptor variants in patients on antiplatelet therapy, complemented by standardized quantification of platelet function, can provide useful information for future drug design studies and possibly for personalized antiplatelet therapy and prevention of @entity715 events. Additional information is, however, needed to evaluate the cost-effectiveness of complex genetic and platelet function testing.
